Fractyl Health, Inc. (GUTS) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
3 Van de Graaff Drive
Burlington, MA 01803
United States of America (the)
Phone
781-902-8800
Website
Sector
Healthcare
Industry
Biotechnology
Employees
102
First IPO Date
February 02, 2024
| Name | Title | Pay | Year Born |
| Harith Rajagopalan | Co-Founder, Chief Executive Officer & Director | 976,422 | 1977 |
| Lara Smith Weber | Chief Financial Officer & Treasurer | 580,985 | 1975 |
| Sarah S. Toomey | General Counsel & Corporate Secretary | 638,648 | 1975 |
| Jay D. Caplan BSEE | Co-Founder, Chief Product Officer & President | 666,858 | 1962 |
| Brian Luque | Head of Investor Relations & Corporate Development | 0 | N/A |
| Jon Fitzgerald | Senior Vice President of Regulatory, Quality & Clinical | 0 | N/A |
| Mike Zumdahl | Senior Vice President of Market Access & Commercial Strategy | 0 | N/A |
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.